@DCVaxDefender
Account based inNorth America
About this account
- Account based in
- North America
- Connected via
- North America Android App
Account-level information from X, not a live location or the device used for a specific post.
The UK NHS explicitly stated they are building nationwide logistics for $NWBO DCVax-L to support GBM "as well as all solid tumours."
โWe do not yet know the exact regulatory sequence to a broad solid tumor label.
Yet the UK single-payer system is making one thing clear: they are planning for full platform scale and they are building the physical infrastructure to support it right now.
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
ANOTHER NAIL IN THE COFFIN OF THE AI TRADE
The Financial Times reports that OpenAIโs annualized revenue was approaching $50 billion at the end of September, against the $70 billion the market had been talking about. Thatโs yet another nail in the coffin of the AI trade.
Weโre reiterating our calls and doubling down on our shorts in these 3 names:
substack.com/@georgenoble/noโฆ
Joined @DeanBaker13 to talk about Amazonโs $8 billion chip deal, the massive wall of compute commitments from AI labs, and Oracleโs dangerous game with OpenAI.
youtu.be/rHaPfdnRoZ4?si=GqLZโฆ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
Itโs been a very long and winding road for us $NWBO longs, however the countdown has begun!๐ค๐
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
Nick Saban says he had lived his entire life like he was in a hurry and didnโt even realize it
โWhen I retired, and I donโt know if I ever shared this with anybody, I spent 50 years of my life being in a hurry and didnโt know it.โ
โI retired and the cars are backed up on the bridge and it goes down to one lane. In the old days, I would be the guy that passed all the cars up and cut in at the last minute in front of somebody.โ
โI sat there with Miss Terry in the car. She says, โYou mean youโre not going to pass everybody illegally and cut in?โ I said, โWeโre not in a hurry.โโ
โBut itโs the first time when I retired that I realized that I wasnโt in a hurry. And I was in a hurry for 50 years and didnโt know it.โ
โI was always hurrying up to the next thing. Solve the next problem, go to the next thing. And you talk about relieving stress, that relieves stress better than anything. I just noticed it in that circumstance. Not cutting into traffic and waiting my turn.โ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
$NWBO NHSBT has never collaborated with a company who later was denied MHRA approval. Galapagos NV fell through, but before they even applied for approval. All others eventually were approved. We are finally at the finish line. Congrats to those who have chosen to stick around.
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
We got youโฆ @exosome
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
Government Agencies and healthcare companies canโt use โTreatmentโ lightly. Unless Iโm missing something โฆ.. Please fill in the blank ๐ $NWBO
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
Who calls it a treatment? $NWBO
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
$NWBO
On the news today regarding NHS and NWBO cooperation
lnkd.in/p/en8ghrir
Once again clear proof of the quality of the due diligence work some of us goes to length to provide to the community, with deep humble respect from me to the likes of @andrewcaravello, @peter_brit, @d_stock07734, @TomBaxers, @hoffmann6383, @HenryMuney, @ATLnsider, @maveric92283613, @DCVaxDefender, @Dave46217976, @SouthernDrive21 @EatYerShorts - and many more - who tries DAILY to counter the paid bashing Judas coin earning collective on Investorshub.
You can read more deep researched analysis on nwbo-community.com a site built to restrict bullshitters from polluting real due diligence.
With regards to this extremely positive news today:
I asked :
โassess the NHS news and correlate with the content of these 3 articles I made 1-2 years ago and please sum up concisely, how I imagined the future for nwbo and dcvax-l in the UK.โ
Answer:
You envisaged the UK becoming NWBOโs base for a scalable, NHS-connected DCVax-L network: Sawston providing central manufacturing expertise and quality oversight, NHS facilities bringing services closer to patients, and Flaskworks EDEN improving production capacity and economics.
What your three articles anticipated
Eleanorโs Journeyโ
nwbo-community.com/vault/c15โฆ
translated that vision into a fictional patientโs experience after approval: local cell collection, processing and oversight through Sawston, eventual EDEN manufacturing at a regional hospital, and treatment near home. You explicitly included NHS Blood and Transplant among the organisations capable of supporting this network. (Pages 5โ16, 21โ24.)
Flaskworks EDEN: Building a Decentralized Point-of-Care Networkโ
nwbo-community.com/vault/b87โฆ
supplied the operational proposal: use existing NHS and academic facilities, begin with selected UK sites, expand nationally, and use that experience to support international expansion. NHSBTโs cell isolation, cryopreservation and national logistics capabilities were specifically identified. (Pages 5, 8, 25.)
The UKโs New Regulatory Architecture
nwbo-community.com/vault/561โฆ
โ explained your regulatory and economic expectations, with funded, routine NHS access as the ultimate objective. This paper described a different manufacturing arrangement: complete vaccine batches made at Sawston, with hospitals storing and preparing doses locally. (Pages 5, 10.)
How the NHS news fits
The 8 October 2026 announcement establishes NHSBT support for immune-cell collection and specialist processing, working with NWBO and Advent, initially in Leeds and Oxford, with wider expansion being explored. That directly corresponds to the institutional partnership and distributed services you described.
The strongest correspondence is specific: you identified NHSBT itself and the capabilities now being put to use. This materially supports your infrastructure thesis.
The broader vision still has further stages: hospital-based EDEN manufacturing, NHS reimbursement and routine access. Your explanation of the review period as regulatory co-development remains an interpretation. The announcement describes DCVax-L as experimental and its marketing application as still under review.
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVaxยฎ-L Production
prnewswire.com/news-releasesโฆ
$NWBO
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
I have recently received a harsh personal attack...and my board members @immortabio have been contacted...by people complaining that I support $NWBO
You know what this means?
WAR
I shall amplify my posts supporting the most advanced and promising dendritic cell technology !
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
The most important sentence I see regarding #NHS collaboration to support manufacturing of $NWBO #DCVax throughout the UK is: โas well as all solid tumorsโ. This network of leukapheresis centers throughout UK will support โall solid tumor cancers:
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
$NWBO
#DCVax #DCVaxForBraelyn #GBM #Glioblastoma #SolidTumors #CancerResearch #Immunotherapy #BTSM
๐๐ถ๐ป๐ฑ๐ฎ ๐ฃ๐ผ๐๐ฒ๐ฟ๐ | ๐๐ต๐ฎ๐ถ๐ฟ & ๐๐๐ข, ๐ก๐ผ๐ฟ๐๐ต๐๐ฒ๐๐ ๐๐ถ๐ผ๐๐ต๐ฒ๐ฟ๐ฎ๐ฝ๐ฒ๐๐๐ถ๐ฐ๐
๐๐ป๐ป๐๐ฎ๐น ๐ฆ๐๐ผ๐ฐ๐ธ๐ต๐ผ๐น๐ฑ๐ฒ๐ฟ ๐ ๐ฒ๐ฒ๐๐ถ๐ป๐ด | ๐๐ฒ๐ฐ๐ฒ๐บ๐ฏ๐ฒ๐ฟ ๐ฎ๐ต, ๐ฎ๐ฌ๐ฎ๐ฑ
On the MHRAโs work reviewing the companyโs application:
โ๐ง๐ต๐ฒ ๐ณ๐ถ๐ฟ๐๐ ๐๐ต๐ถ๐ป๐ด ๐ ๐ฐ๐ฎ๐ป ๐๐ฎ๐, ๐ฎ๐ป๐ฑ ๐ถ๐โ๐ ๐พ๐๐ถ๐๐ฒ ๐ถ๐บ๐ฝ๐ผ๐ฟ๐๐ฎ๐ป๐, ๐ถ๐ ๐๐ต๐ฎ๐ ๐๐ฒ ๐ฎ๐ฟ๐ฒ ๐ฟ๐ฒ๐ฎ๐น๐น๐, ๐ฟ๐ฒ๐ฎ๐น๐น๐ ๐ด๐ฟ๐ฎ๐๐ถ๐ณ๐ถ๐ฒ๐ฑ ๐ฏ๐ ๐ต๐ผ๐ ๐บ๐๐ฐ๐ต ๐๐ผ๐ฟ๐ธ ๐ฎ๐ป๐ฑ ๐ต๐ผ๐ ๐บ๐๐ฐ๐ต ๐ฟ๐ฒ๐๐ผ๐๐ฟ๐ฐ๐ฒ๐ ๐๐ต๐ฒ ๐ฎ๐ด๐ฒ๐ป๐ฐ๐ ๐ถ๐ ๐ฑ๐ฒ๐๐ผ๐๐ถ๐ป๐ด ๐๐ผ ๐ผ๐๐ฟ ๐ฐ๐ฎ๐๐ฒ. ๐ง๐ต๐ฒ๐โ๐ฟ๐ฒ ๐ฑ๐ผ๐ถ๐ป๐ด ๐ฎ๐ป ๐ฒ๐ป๐ผ๐ฟ๐บ๐ผ๐๐ ๐ฎ๐บ๐ผ๐๐ป๐ ๐ผ๐ณ ๐๐ผ๐ฟ๐ธ ๐ผ๐ป ๐ผ๐๐ฟ ๐ฐ๐ฎ๐๐ฒ, ๐ถ๐ป๐๐ฝ๐ฒ๐ฐ๐๐ถ๐ผ๐ป๐ ๐ฎ๐ป๐ฑ ๐ฎ๐ป๐ฎ๐น๐๐๐ฒ๐ ๐ฎ๐ป๐ฑ ๐๐ผ ๐ณ๐ผ๐ฟ๐๐ต. ๐๐ป๐ฑ ๐ผ๐๐ฟ ๐ฎ๐ฑ๐๐ถ๐๐ผ๐ฟ๐ ๐ต๐ฎ๐๐ฒ ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐๐ฒ๐ฑ ๐ผ๐ป ๐๐ต๐ถ๐ ๐๐ผ๐ผ, ๐ฎ๐ป๐ฑ ๐ต๐ฎ๐๐ฒ ๐ฒ๐
๐ฝ๐ฟ๐ฒ๐๐๐ฒ๐ฑ ๐๐ผ ๐๐ ๐๐ต๐ฎ๐ ๐๐ต๐ฒ๐ ๐ฎ๐ฟ๐ฒ ๐ถ๐บ๐ฝ๐ฟ๐ฒ๐๐๐ฒ๐ฑ ๐๐ถ๐๐ต ๐๐ต๐ฒ ๐ฎ๐บ๐ผ๐๐ป๐ ๐ผ๐ณ ๐ฟ๐ฒ๐๐ผ๐๐ฟ๐ฐ๐ฒ๐ ๐ฏ๐ฒ๐ถ๐ป๐ด ๐ฑ๐ฒ๐๐ผ๐๐ฒ๐ฑ. ๐ฆ๐ผ ๐๐ต๐ฎ๐โ๐ ๐ฎ ๐ฝ๐ผ๐๐ถ๐๐ถ๐๐ฒ, ๐ฎ๐ป๐ฑ ๐๐ฒโ๐ฟ๐ฒ ๐ด๐ฟ๐ฎ๐๐ถ๐ณ๐ถ๐ฒ๐ฑ ๐ฏ๐ ๐ถ๐.โ
On the MHRAโs evolving approach to external controls:
โ๐๐ผ๐ฟ ๐ฒ๐
๐ฎ๐บ๐ฝ๐น๐ฒ, ๐ถ๐ป ๐ ๐ฎ๐ ๐ผ๐ณ ๐๐ต๐ถ๐ ๐๐ฒ๐ฎ๐ฟ, ๐๐ต๐ฒ ๐ ๐๐ฅ๐ ๐ถ๐๐๐๐ฒ๐ฑ ๐ฎ ๐ฑ๐ฟ๐ฎ๐ณ๐ ๐ด๐๐ถ๐ฑ๐ฎ๐ป๐ฐ๐ฒ ๐ฑ๐ผ๐ฐ๐๐บ๐ฒ๐ป๐ ๐๐ต๐ฎ๐ ๐๐ผ๐๐น๐ฑ ๐ด๐ถ๐๐ฒ ๐ฝ๐ฒ๐ฟ๐บ๐ถ๐๐๐ถ๐ผ๐ป ๐ณ๐ผ๐ฟ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐ถ๐ฎ๐น๐ ๐๐ผ ๐๐๐ฎ๐ฟ๐ ๐๐๐ถ๐ป๐ด ๐ฒ๐
๐๐ฒ๐ฟ๐ป๐ฎ๐น ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น๐, ๐ฎ๐ป๐ฑ ๐ ๐๐ฅ๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ๐ฑ ๐ฝ๐๐ฏ๐น๐ถ๐ฐ ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐ ๐ฎ๐น๐น ๐๐ต๐ฟ๐ผ๐๐ด๐ต ๐๐ต๐ฒ ๐๐๐บ๐บ๐ฒ๐ฟ. ๐ข๐๐ฟ ๐๐ป๐ฑ๐ฒ๐ฟ๐๐๐ฎ๐ป๐ฑ๐ถ๐ป๐ด ๐ถ๐ ๐ถ๐ ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ๐ฑ ๐น๐ผ๐๐ ๐ผ๐ณ ๐ฐ๐ผ๐บ๐บ๐ฒ๐ป๐๐, ๐๐ฒ๐ฟ๐ ๐ฝ๐ผ๐๐ถ๐๐ถ๐๐ฒ. ๐๐ป๐ฑ ๐ผ๐๐ฟ ๐๐ป๐ฑ๐ฒ๐ฟ๐๐๐ฎ๐ป๐ฑ๐ถ๐ป๐ด ๐ถ๐ ๐๐ต๐ฎ๐ ๐ถ๐ป ๐๐ต๐ฒ ๐ฒ๐ฎ๐ฟ๐น๐ ๐ณ๐ฎ๐น๐น, ๐๐ต๐ฒ ๐ ๐๐ฅ๐ ๐ฎ๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ๐ฑ ๐๐ต๐ฎ๐ ๐ถ๐ ๐ป๐ผ๐ ๐ฝ๐น๐ฎ๐ป๐ ๐๐ผ ๐บ๐ฎ๐ธ๐ฒ ๐๐ต๐ฎ๐ ๐ณ๐ผ๐ฟ๐บ๐ฎ๐น ๐ฎ๐ป๐ฑ ๐ถ๐ป๐ฑ๐ฒ๐ณ๐ถ๐ป๐ถ๐๐ฒ. ๐ง๐ต๐ฎ๐โ๐ ๐ต๐๐ด๐ฒ. ๐ง๐ต๐ฎ๐โ๐ ๐ฎ๐บ๐ฎ๐๐ถ๐ป๐ด, ๐ด๐ถ๐๐ฒ๐ป ๐ต๐ผ๐ ๐บ๐๐ฐ๐ต ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐๐ฒ๐ฟ๐๐ ๐๐ต๐ฒ๐ฟ๐ฒ ๐ต๐ฎ๐ ๐ฏ๐ฒ๐ฒ๐ป ๐ผ๐๐ฒ๐ฟ ๐๐ต๐ฎ๐ ๐๐๐ฏ๐ท๐ฒ๐ฐ๐.โ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
I will keep reposting this until we raise enough money to ensure that Braelyn finishes her treatments. If 10% of NWBO's 35,000 retail investors gave $25-$30 , she would be safe. If she allows herself to be the face of DCVax's potential, then we should help her in her journey!
$NWBO
The miracle of Braelyn
With help from Braelyns mother Amanda, we have made a presentation, that documents Braelyns incredible journey the last 3 years.
Please share.
There is a link to donation site, if you would care to help ๐
nwbo-community.com/news/15c6โฆ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
First injection of stem cells into penis...
I am humbled to have been the first author !!!
pmc.ncbi.nlm.nih.gov/articleโฆ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
This is the new reality that will change the way we look at not only cancer but many other diseases. Please read...
The $NWBO #DCVax platform is antigen agnostic. It works on every disease.
Steinman spent a career proving that the elegant addressed vaccine was the answer. His own cancer proved he'd asked the wrong question. The cell that won't respond to the perfect address isn't broken, it's converted. Irreversibly. So the solution isn't to address it better. It's to replace it.
He discovered this by using manufactured cells on himself and getting four and a half years instead of six months. Then he refused to publish it as evidence, because one patient isn't a trial. He had spent decades arguing that mail delivery was the problem to solve. His own body proved the problem was that the recipient had moved and had no intention of moving back.
One platform. Any payload. Built outside the field, delivered inside the body, instructing once.
#DCVaxForBraelyn
nitter.cf/andrewcaravello/statusโฆ
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
$NWBO
Preventing recurrence is extremely important in cancer treatment. The long peptides that are bonded with MHC Class II molecules on the surface of DCs are the ones that engage CD4 T-cells vital for immune memory.
Only very few types of cells have MHC Class II molecules: dendritic cells, B cells, and macrophages.
Can CAR-T present tumor-associated antigens existing in both normal cells and cancer cells to immune system?
Can peptide vaccines present tumor-associated peptides existing in both normal cells and cancer cells?
What about mRNA cancer vaccines?
All those short and long peptides listed in the figure are tumor-associated peptides that can be found in both tumor tissue and normal tissue. DCVax-L can make immune system eliminate cancer cells while sparing normal cells. Is there another treatment more amazing than this one? NO!!!
autologous assassin ๐บ๐ธ๐จ๐ฑโ๏ธ๐ดโโ ๏ธ retweeted
$NWBO
The results from ovarian cancer trial are truly amazing.
Those researchers didn't stop in 2013. They went onwards, ran more trials with various combinations, and produced good results. For instance, in a trial on ovarian cancer, in cohort C which is the combination of the following:
Cyclophosphamide + DC vaccine given intranodally + Roche's bevacizumab (VEGF inhibitor) + Aspirin + IL-2
80% of patients had OS greater than three years. Those patients are mostly alive today because immune memory was activated.
Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
pmc.ncbi.nlm.nih.gov/articleโฆ
Personalized cancer vaccine strategy elicits polyfunctional T cells and demonstrates clinical benefits in ovarian cancer
nature.com/articles/s41541-0โฆ
From LP at ASM:
And just one last thing to remind you on that: Northwest already has a history itself in ovarian cancer. You may remember that we did a small pilot trial with DCVax-L in ovarian cancer, and it was quite strikingly encouraging at the time. We could only do the small pilot, but the academic collaborators we did that trial with many years ago, who were at Penn, and Penn has a center of excellence in ovarian cancer, they did go onwards and treat some more patients beyond what we could do, and they continued to get good results, and those results have been published.
So itโs very encouraging to have this next stage of clinical development and the combo trial be in an area where we already have prior data indicating that the dendritic cells have done a really nice job, at least in that context.
